Nature Mental Health
May 1, 2025
Daniel H. Grossman, Kevin R. Madden, Nicky J. Mehtani et al.
10 citations
Socioeconomic status (SES) strongly affects mental health outcomes and treatment access, but its reporting in psychedelic-assisted therapy trials is inadequate. A systematic review of 98 articles (49 primary trials and 49 secondary analyses) from 2006 to 2024 found that only 12% of primary trials reported participant income data, and 31% reported educational attainment. In US-based trials, participants had markedly higher SES than the general population: 93% had some college education (versus 62% nationally), and median incomes in major trials substantially exceeded the national median for all workers. Non-US trials showed variable patterns. This underreporting and evidence of socioeconomic disparities highlights an urgent need for standardized SES reporting and strategies to improve socioeconomic diversity in psychedelic-assisted therapy research.
JAMA Network Open
May 7, 2026
Peter S. Hendricks, Sara Lappan, Richard C. Shelton et al.
4 citations
A single 25 mg dose of psilocybin, combined with psychotherapy, led to a higher percentage of cocaine-abstinent days, a greater likelihood of complete abstinence, and a longer time before the first cocaine lapse over 180 days compared with an active placebo (100 mg diphenhydramine) in a randomized, quadruple-blind trial. Among 40 participants with cocaine use disorder, 33 were men, 33 were Black, and most had low income. Psilocybin appeared safe, with no serious adverse events, and may offer a treatment for cocaine use disorder in underrepresented populations.
Front Psychiatry
December 9, 2025
Haley Maria Dourron, Heith Copes, Daniel H. Grossman et al.
3 citations
People diagnosed with non-affective psychotic disorders who used psychedelics reported a mix of positive and negative effects. Common challenges during the acute experience included transient anxiety, sometimes leading to brief hospitalizations. Some participants described psychosis-specific experiences such as reduced self-stigma and insight into their hallucinations and delusions. Perceived long-term benefits varied widely, with some reporting lasting positive changes and others noting negative effects or no lasting impact. The findings suggest psychedelics may pose both risks and potential benefits for this population, highlighting the need for careful safety trials.